Search

Immunocore Holdings PLC ADR

Fechado

37.06 0.98

Visão Geral

Variação de preço das ações

24h

Atual

Mín

35.4

Máximo

36.79

Indicadores-chave

By Trading Economics

Rendimento

-14M

-786K

Vendas

9.3M

116M

EPS

-0.02

Margem de lucro

-0.678

Funcionários

524

EBITDA

-13M

3.6M

Recomendações

By TipRanks

Recomendações

Comprar

Previsão para 12 meses

+70.36% upside

Dividendos

By Acuity

Próximos Ganhos

5 de nov. de 2026

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

155M

1.8B

Abertura anterior

36.08

Fecho anterior

37.06

Immunocore Holdings PLC ADR Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

24 de ago. de 2026, 20:06 UTC

Immunocore Holdings PLC shares are lower amid rising oil prices and geopolitical tensions, including new U.S. sanctions against Iran. No specific company news was identified.

21 de ago. de 2026, 19:46 UTC

News

IMCR gains as JPMorgan reinstates coverage with Overweight rating.

20 de ago. de 2026, 20:02 UTC

Immunocore Holdings PLC shares are lower today, reflecting declines in the Biotechnology sub-sector. The stock has shown notable volatility during the session.

19 de ago. de 2026, 22:51 UTC

Immunocore Holdings PLC shares are higher in after-market hours, continuing an upward trend. No specific news was identified to explain the movement.

18 de ago. de 2026, 20:01 UTC

Immunocore Holdings PLC is rising amid biotechnology sector strength, despite pulling back from an earlier session high. No specific company news was identified.

17 de ago. de 2026, 19:23 UTC

News

Immunocore Holdings PLC shares are higher today following HC Wainwright's improved Q3 2026 earnings estimates, raising loss per share projections to -$0.08 from -$0.25.

14 de ago. de 2026, 22:16 UTC

Immunocore Holdings PLC shares are lower in after-market trading. Broader market sentiment is impacted by declining retail sales and consumer confidence.

11 de ago. de 2026, 20:01 UTC

Immunocore Holdings PLC is rising as biotechnology sector strength supports shares, though the stock has pulled back from an earlier session high.

10 de ago. de 2026, 19:16 UTC

News

Immunocore Holdings PLC reports second-quarter revenue of $115.93 million, with shares lower amid broader market trends and declining U.S. stock futures.

7 de ago. de 2026, 20:04 UTC

News

Immunocore Holdings reported a wider Q2 loss of 2 cents per share and $115.9 million in revenue, with shares trading lower since Thursday's close.

6 de ago. de 2026, 19:52 UTC

News

Immunocore Holdings PLC reported Q2 earnings of -$0.02 per share and revenue of $115.93 million, exceeding expectations. Shares are trading higher during Thursday's session.

5 de ago. de 2026, 20:02 UTC

Immunocore Holdings PLC is higher today, reflecting broader gains in the Biotechnology sector. No specific company news was identified to explain the movement.

4 de ago. de 2026, 19:51 UTC

Immunocore Holdings PLC shares are higher today amid broader market strength and a notable decline in crude oil prices, easing inflation concerns.

3 de ago. de 2026, 20:03 UTC

News

Immunocore Holdings PLC is declining in Monday's session, diverging from gains in major tech stocks and remaining below its 20-day moving average.

31 de jul. de 2026, 20:06 UTC

Immunocore Holdings PLC shares are lower today, with no specific news identified. The stock has fluctuated within a routine range during the session.

28 de jul. de 2026, 19:56 UTC

Immunocore Holdings PLC shares are lower today, continuing a three-session decline amid broader market sentiment influenced by declines in Asian markets.

27 de jul. de 2026, 18:06 UTC

Immunocore Holdings PLC shares are lower today, reflecting a broader market trend amid a significant decline in oil prices. No specific company news was identified.

24 de jul. de 2026, 15:26 UTC

Immunocore Holdings PLC shares are lower today, having declined from a session high. This movement occurs amid mixed labor market data and inflation concerns.

22 de jul. de 2026, 19:16 UTC

News

Immunocore Holdings PLC shares are higher as Wall Street Zen upgraded its rating to "buy," despite a mixed analyst outlook.

21 de jul. de 2026, 21:01 UTC

Immunocore Holdings PLC shares are higher in after-market trading, driven by optimistic sentiment in U.S. markets and better-than-expected results from major companies.

20 de jul. de 2026, 20:06 UTC

News

Immunocore Holdings PLC shares are lower amid broader market weakness. Analyst ratings show mixed sentiment, with upgrades and downgrades influencing performance.

Comparação entre Pares

Variação de preço

Immunocore Holdings PLC ADR Previsão

Preço-alvo

By TipRanks

70.36% parte superior

Previsão para 12 meses

Média 62.83 USD  70.36%

Máximo 100 USD

Mínimo 35 USD

Com base em 6 analistas de Wall Street que oferecem metas de preço de 12 meses para Immunocore Holdings PLC ADR - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

6 ratings

4

Comprar

2

Manter

0

Vender

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Immunocore Holdings PLC ADR

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.
help-icon Live chat